OncoMatch/Clinical Trials/NCT06108232
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
Is NCT06108232 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Obinutuzumab and CC-99282 for follicular lymphoma.
Treatment: Obinutuzumab · CC-99282 — To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CD20 monoclonal antibody
Prior exposure to CD20 mAb
Cannot have received: IMiD
Prior exposure to IMiDs
Lab requirements
Blood counts
Hemoglobin ≥ 8 g/dL (if no bone marrow involvement); Platelets ≥ 75 x 10^9/L (if no bone marrow involvement); Absolute neutrophil count (ANC) ≥ 1.5x10^9/L (if no bone marrow involvement)
Kidney function
Creatinine clearance >50 ml/min calculated by modified Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 ULN, unless consistent with Gilbert's (ratio between total and direct bilirubin > 5); AST and ALT ≤ 3x upper limit of normal (ULN); Alkaline phosphatase < 2.5 ULN
Cardiac function
No clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification. No significant screening ECG abnormalities including left bundle branch block, 2nd degree atrioventricular (AV) block, type II AV block, or 3rd degree block. QTcF < 470 msec.
Patients must have adequate organ and marrow function as defined below: Total bilirubin ≤ 1.5 ULN, unless consistent with Gilbert's (ratio between total and direct bilirubin > 5); AST and ALT ≤ 3x upper limit of normal (ULN); Alkaline phosphatase < 2.5 ULN; Creatinine clearance >50 ml/min calculated by modified Cockcroft-Gault formula; Blood counts below if without bone marrow lymphoma involvement: Hemoglobin ≥ 8 g/dL; Platelets ≥ 75 x 10^9/L; Absolute neutrophil count (ANC) ≥ 1.5x10^9/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify